30 Jun The Potential Risks of Using Ozempic and Rybelsus
Ozempic and Rybelsus are medications that have become increasingly popular for managing type 2 diabetes and, more recently, for off-label use in weight loss. Both drugs contain semaglutide, a compound that mimics a hormone that is involved in the regulation of blood sugar and control of appetite. These drugs do work for many patients, but they are not without risk. With their use increasing, concern has grown over potential side effects.
As more patients turn to these medications, it’s essential to weigh the benefits against the risks. Understanding how each drug affects the body can help make safer choices. That’s why an Ozempic vs Rybelsus safety comparison is key for anyone considering these treatments.
1. Gastrointestinal Issues
One of the most common side effects patients report experiencing with Ozempic and Rybelsus is gastrointestinal discomfort. Patients often report nausea, vomiting, diarrhea, and abdominal pain, especially when treatment is initiated or the dose is adjusted.
These symptoms can be mild and last a few weeks. Such discomfort is sometimes severe enough to result in dehydration or discontinuation of therapy. This can exacerbate symptoms in individuals who already have other pre-existing digestive problems.
2. Pancreatitis
A more severe potential side effect of semaglutide-based drugs is pancreatitis or irritation of the pancreas. Although rare, this condition can be fatal if left untreated. Symptoms include severe abdominal pain, which may radiate to the back, nausea, and vomiting.
Patients with a history of pancreatitis or gallstones may face a higher risk and should be closely monitored. This risk of pancreatitis is addressed in the drug’s labeling, and physicians advise stopping the medication if pancreatitis is suspected.
3. Thyroid C-Cell Tumors
Concerns have been raised about thyroid C-cell tumors. Animal studies involving semaglutide have reported an increased frequency of these tumors, including medullary thyroid carcinoma.
Although the applicability of these results in humans is unknown, patients with a personal and family history of thyroid cancer, especially medullary thyroid carcinoma, are usually advised to avoid these drugs.
4. Hypoglycemia
While Ozempic and Rybelsus don’t usually cause dangerously low blood sugar by themselves, these drugs can increase the risk of hypoglycemia when they’re used with other diabetes drugs, including insulin and sulfonylureas.
Symptoms of low blood sugar can include shakiness, confusion, sweating, and dizziness. In extreme cases, it may lead to unconsciousness or seizures. Adjusting other medications and closely monitoring blood sugar levels can help reduce the likelihood of this side effect.
5. Kidney Problems
Finally, there have been reports of kidney problems, including acute kidney injury, in patients on semaglutide. These problems can be due to severe dehydration from recalcitrant nausea, vomiting, or diarrhea.
People who have existing kidney problems certainly should be cautious because causing any more damage can cause long-term complications. Individuals at higher risk of kidney problems may undergo regular kidney function tests while receiving treatment.
Conclusion
Ozempic and Rybelsus are powerful anti-diabetes and anti-obesity weapons; however, they are not without risks. Patients should be fully informed about gastrointestinal discomfort and more severe side effects like pancreatitis and thyroid tumors before beginning the treatment.
A conversation with a healthcare professional, a review of the medical history, and regular observation can help assess whether the benefits of these medications outweigh the risks.
——
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Some links are sponsored. Products and services are not endorsed.
Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on June 30, 2025 by Marie Benz MD FAAD
